By Ashley Zborowski, Director of Business Development, LSN

The Redefining Early Stage Investment (RESI) Service Provider Showcase helps companies gain unprecedented visibility into the early-stage life science community and leverages Life Science Nation (LSN)’s close-knit network of key decision-makers to make promising connections with future clients.  Service providers are an important asset in the fundraising ecosystem, and this new program is designed to increase their exposure to the RESI community.

Digital RESI, June 8-10, proudly features service providers advancing early-stage startups within drugs, devices, diagnostics, and digital health. Often the unsung heroes of fundraising startups, these powerful partnerships are essential in commercializing, building teams, conducting research, manufacturing, and so much more! Meet and get to know some featured service providers at Digital RESI June, and contact us to learn more about this special offer.

MERIT

MERIT is an innovative specialty CRO providing clinical trial data collection and interpretation in the ophthalmology and respiratory disciplines. Our portfolio of solutions offers deep clinical expertise, unique technology, and exceptional service for our partners, sponsors, and CROs.

PharmaDirections

At PharmaDirections, gain access to top talent without the cost or risk of a full-time, in-house team. More than just a consultant or outside vendor, we are an extension of your team and are accountable for all aspects of a project, from discovery to regulatory approval.

SPH Phililab

SPH Phililab an innovation pharmaceutical company that develop, registrar, and manufacture generic and modified new drug product in USA and China. Our product portfolio focuses on the two largest pharmaceutical markets in the world, plus our unique background of management team and scientists made us a pioneer as an international player in the pharmaceutical industry.

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Fundraising is a numbers game, and early-stage executives need to know that the odds are stacked in their favor when seeking capital and meeting with investors and strategic partners. Since Digital RESI March last year, 3,500+ investors from 700 unique firms have joined in Life Science Nation (LSN)’s virtual partnering events. Of these unique firms, over 70% have been repeat attendees and over half of those have attended more than five conferences since March 2020.

Investors are enthusiastically leveraging digital partnering to seek quality deal flow for potential investment, strategic partnership, in-licensing, and more. Fundraising executives aren’t the only ones who know partnering is a numbers game.  They are showing up consistently to connect with the latest technology in drugs, devices, diagnostics, and digital health. To learn more, get involved, and take advantage of these trends, contact the RESI team and check out the upcoming Digital RESI, June 8-10. 

By Karen Deyo, Director of Investor Research, Israel BD, LSN

The Life Science Nation (LSN) team has already gathered an exciting lineup of panelists for our Digital Redefining Early Stage Investments (RESI) conference, taking place June 8-10. Whether from organizations that have contributed to RESI in the past, or those speaking for the first time, panelists will contribute dynamic conversations and provide useful tips for fundraising startups. Here is a spotlight on some of the speakers who will be joining us in June!

Faz Bashi Member of BOD Life Science Angels	Anna Turetsky Principal, Venture Investments The Mark Foundation for Cancer Research	Juan Cueva Senior Associate Action Potential Venture Capital
Miles Gerson Partner Takeda Ventures	Sam Goldberger Partner Ambit Health Ventures	Brian Meshkin Managing Partner, Profound Ventures Partner, Cancer Fund
John Parker Founder & Managing Director Springhood Impact Ventures	Richard Proscia Senior Associate Providence Ventures	Yaniv Sneor Founding Member Mid Atlantic Bio Angels

Register by May 7 to save $50 and hear from these panelists and to schedule meetings with the below investors who are participating in RESI!

Confirmed Digital RESI June Investors and Strategic Partners*

*April 15, 2021

By Caitlin Dolegowski, Marketing Specialist, LSN

The impact of the COVID-19 pandemic will be lasting – creating both opportunities and challenges in the digital health sector. At last month’s Healthtech Partnering Week, these were popular themes throughout investor panels across the three early-stage partnering events, Digital RESI March, 4D Meets AI, and Longevity, Health & Innovation.

A main theme from investors participating in these panels is the sheer enormity of the opportunities in digital health. Dr. Stephen Pitt, Head of JLabs US North East kicked off the 4D Meets AI Digital Health panel by saying, “2020 was certainly a turning point for digital health. I think we saw the pandemic help accelerate some areas, such as telehealth.” The Digital Health for the Elderly panel at Longevity, Health & Innovation reiterated Dr. Pitt’s statement through a conversation surrounding the needs for access to high-quality telehealth services for seniors. This point was furthered in Digital RESI March’s panel by Relentless Venture Fund’s Managing Partner, Brenda Irwin, who stated, “$14.1B was deployed in digital health in 2020, which was a 72% increase from the most active year, which was 2018.” Additionally, major players like Microsoft are advancing the need for digital health advancements through their recent acquisition of AI and tech company, Nuance Communications for $16B.

Early-stage entrepreneurs are in a prime moment of investment opportunity. Some of the pre-pandemic emerging digital health ideas are now the new normal and the industry is at the tip of the iceberg of innovation. Health Equity Capital Managing Partner, Taja Lester highlighted a virtual healthtech advancement where 3,500 Parkinson’s patients participated in a clinical trial conducted by the National Institute of Aging entirely from patients’ homes. Additionally, technology is advancing; smart phones, wearables, tablets, etc. can now provide biomarkers remotely. This also contributes to provider interoperability, which allows for an entire care team to have access to all the information specific to them in one location. These improvements have been “drastically accelerated and made necessary by COVID,” according to Justin Kelly, Associate at AXA Venture Partners.

Functional versus personable partnering is also an undercurrent highlighted by digital access. In-person relationship-building can never be fully replaced with these remote technological advancements. “I think the personal connection is a very important part of how you find an early investor and how you get somebody on board that sees the problem the way you do because you have something really strong in common to go through the different phases that a start-up goes through,” says Syllable Co-Founder and CEO, Kobus Jooste.

With the rise of COVID-19 vaccinations, in-person events may be on the horizon. Whether partnering continues virtually or through a hybrid or in-person model, the applications of digital health advancement are likely here to stay, and will continue creating value for patients, providers, and partnerships. If you’re ready to dive into match-based partnering that fits your product and stage of development, register for Digital RESI, June 8-10 at early bird rates until May 7.